Evidence map›Paper›PMID 29936534›Full record

ArticleCancer immunology, immunotherapy : CII2018

Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients.

Valeria I Segatori, Héctor A Cuello, Cynthia A Gulino, Marina Albertó, Cecilia Venier, Marcelo D Guthmann, Ignacio A Demarco, Daniel F Alonso, Mariano R Gabri

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Structural and Functional Mise en Abyme.Frontiers in molecular biosciences · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Valeria I SegatoriMolecular Oncology Laboratory, National University of Quilmes, Roque Saenz Peña 352, Bernal, B1876BXD, Argentina.ORCID http://orcid.org/0000-0002-3913-3658
Héctor A CuelloMolecular Oncology Laboratory, National University of Quilmes, Roque Saenz Peña 352, Bernal, B1876BXD, Argentina.
Cynthia A GulinoMolecular Oncology Laboratory, National University of Quilmes, Roque Saenz Peña 352, Bernal, B1876BXD, Argentina.
Marina AlbertóMolecular Oncology Laboratory, National University of Quilmes, Roque Saenz Peña 352, Bernal, B1876BXD, Argentina.
Cecilia VenierInstitute of Immunology, Genetics and Metabolism (INIGEM), University of Buenos Aires, Avenida Córdoba 2351, Buenos Aires, C1120AAF, Argentina.
Marcelo D GuthmannElea Laboratories, Sanabria 2353, Buenos Aires, C1417AZE, Argentina.
Ignacio A DemarcoElea Laboratories, Sanabria 2353, Buenos Aires, C1417AZE, Argentina.
Daniel F AlonsoMolecular Oncology Laboratory, National University of Quilmes, Roque Saenz Peña 352, Bernal, B1876BXD, Argentina.
Mariano R GabriMolecular Oncology Laboratory, National University of Quilmes, Roque Saenz Peña 352, Bernal, B1876BXD, Argentina. mrgabri@unq.edu.ar.ORCID http://orcid.org/0000-0001-8395-9222
National University of Quilmes · ARElea (Argentina) · ARUniversidad de Buenos Aires · AR

Funding

National University of Quilmes 1398/15
6 · The paper itself

Abstract

Antitumor strategies based on positive modulation of the immune system currently represent therapeutic options with prominent acceptance for cancer patients' treatment due to its selectivity and higher tolerance compared to chemotherapy. Racotumomab is an anti-idiotype (anti-Id) monoclonal antibody (mAb) directed to NeuGc-containing gangliosides such as NeuGcGM3, a widely reported tumor-specific neoantigen in many human cancers. Racotumomab has been approved in Latin American countries as an active immunotherapy for advanced non-small cell lung cancer (NSCLC) treatment. In this work, we evaluated the induction of Ab-dependent cell-mediated cytotoxicity (ADCC) in NSCLC patients included in a phase III clinical trial, in response to vaccination with racotumomab. The development of anti-NeuGcGM3 antibodies (Abs) in serum samples of immunized patients was first evaluated using the NeuGcGM3-expressing X63 cells, showing that racotumomab vaccination developed antigen-specific Abs that are able to recognize NeuGcGM3 expressed in tumor cell membranes. ADCC response against NeuGcGM3-expressing X63 (target) was observed in racotumomab-treated- but not in control group patients. When target cells were depleted of gangliosides by treatment with a glucosylceramide synthase inhibitor, we observed a significant reduction of the ADCC activity developed by sera from racotumomab-vaccinated patients, suggesting a target-specific response. Our data demonstrate that anti-NeuGcGM3 Abs induced by racotumomab vaccination are able to mediate an antigen-specific ADCC response against tumor cells in NSCLC patients.

Indexed as

Antibody-Dependent Cell CytotoxicityImmunotherapy, ActiveAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedApoptosisCarcinoma, Non-Small-Cell LungG(M3) GangliosideHumansLung NeoplasmsTumor Cells, CulturedAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedG(M3) GangliosideN-glycolylneuraminyllactosylceramideracotumomabActive immunotherapyADCCNeuGcGM3 gangliosideNon-small cell lung cancerRacotumomab

Identifiers

PMID29936534
PMCPMC11028311
OpenAlexW2810535651

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.